Learn more about whether AbbVie Inc. or BeiGene, Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...

Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

AGEP can closely mimic generalized pustular psoriasis (GPP), requiring histopathologic confirmation and assessment of peripheral eosinophilia.

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...

evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis, GPP. “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan ...

The psoriasis treatment that works for you initially may not continue working long term. Some benefits of trying a new treatment can include improved skin clearance, fewer side effects, and saving ...

Suggested remit: To appraise the clinical and cost effectiveness of spesolimab within its marketing authorisation for treating generalised pustular psoriasis flares in adults.